药物洗脱微球栓塞治疗肝转移癌的适应症
|
| study | design | pts. | strategy | oRR (%) | mOS mo | PFS mo |
| Fiorentini 2007 | retrosp. | 20 | salvage | 80 (?) | n.r. | n.r. |
| Martin 2009 | retrosp. | 55 | salvage |
41 mRECIST 6 RECIST |
11 | 8 |
| Narayanan 2013 | retrosp. | 28 | salvage | 45 mRECIST | 13.3 | 4 |
| Huppert 2013 | prosp. | 29 | salvage |
72 mRECIST 0 RECIST |
8 | 5 |
| Iezzi 2015 | retrosp. | 20 | salvage | 10 RECIST | 7.3 | 4.0 |
|
|
|
|
|
|
|
|
| cTACE |
|
|
|
|
8-14 | 3-8 |
DE-TACE in Salvage Patients
 |
 |
 |
| Outcome in Salvage Patients |
降期切除 （Downstaging to Resection）
| study | design | pts. | oRR (%) |
mOS mo |
PFS mo |
Downstaging to resection |
| Martin 2009 | retrosp. | 55 |
41 mRECIST 6 RECIST |
11 | 8 | 6/55 (10%) |
| Akinwande 2016 | prosp. | 15 |
73 mRECIST 33 RECIST |
13 | 8 | 2/15 (13%) |
Consolidation in Liver dominant disease
| study | design | pts. | strategy | oRR (%) | mOS mo | PFS mo |
| Martin 2015 | prosp. | 30 FOLFOX | various | 60 mRECIST | n.a. | 7.6 |
|
30 FOLFOX + DEBIRI |
76 |
|
15.3 |